A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Journal of Translational Medicine
Daniel S GreenChristina M Annunziata

Abstract

Ovarian cancer has no definitive second line therapeutic options, and largely recurs in the peritoneal cavity. Locoregional immune therapy using both interferons and monocytes can be used as a novel approach. Interferons have both cytostatic and cytotoxic properties, while monocytes stimulated with interferons have potent cytotoxic properties. Due to the highly immune suppressive properties of ovarian cancer, ex vivo stimulation of autologous patient monocytes with interferons and infusion of all three agents intraperitoneally (IP) can provide a strong pro-inflammatory environment at the site of disease to kill malignant cells. Patient monocytes are isolated through counterflow elutriation and stimulated ex vivo with interferons and infused IP through a semi-permanent catheter. We have designed a standard 3 + 3 dose escalation study to explore the highest tolerated dose of interferons and monocytes infused IP in patients with chemotherapy resistant ovarian cancer. Secondary outcome measurements of changes in the peripheral blood immune compartment and plasma cytokines will be studied for correlations of response. We have developed a novel immunotherapy focused on the innate immune system for the treatment of ovarian cancer. We ...Continue Reading

References

Apr 22, 1992·International Journal of Cancer. Journal International Du Cancer·N ColomboP Allavena
Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A FaradjiJ P Bergerat
Mar 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P H WillemseD T Sleijfer
Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S Berek
Apr 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R D'AcquistoJ L Lewis
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Pujade-LauraineM Brandely
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BubleyG Wilding
Sep 19, 2003·Gynecologic Oncology·Vivian E von GruenigenKaren M Gil
Mar 18, 2004·Journal of the National Cancer Institute·Gordon J S RustinJan Vermorken
May 3, 2005·Nature Reviews. Immunology·Leonidas C Platanias
Dec 3, 2005·Nature Reviews. Immunology·Siamon Gordon, Philip R Taylor
Jan 6, 2006·The New England Journal of Medicine·Deborah K ArmstrongUNKNOWN Gynecologic Oncology Group
Feb 24, 2007·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Samuel BaronKathryn Zoon
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
May 23, 2009·Nature Reviews. Cancer·Robert C BastGordon B Mills
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Feb 18, 2011·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Samuel BaronKathryn Zoon
Mar 11, 2011·Blood·Katrina SoderquestAlfonso Martín-Fontecha
Jan 8, 2013·Technology in Cancer Research & Treatment·Chunyan LanJihong Liu
Apr 11, 2013·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Joseph BekiszKathryn C Zoon
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A LedermannUNKNOWN ESMO Guidelines Working Group
Dec 18, 2013·Immunological Reviews·Christian S Hinrichs, Steven A Rosenberg
Mar 29, 2014·F1000prime Reports·Fernando O Martinez, Siamon Gordon
Jul 30, 2014·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Chase L JohnsonKathryn C Zoon
Oct 17, 2014·Immunological Reviews·Siamon GordonFernando Martinez Estrada
Jan 17, 2015·Nature·David Artis, Hergen Spits
Dec 28, 2016·Cell Research·Laura A Johnson, Carl H June

❮ Previous
Next ❯

Citations

Feb 19, 2019·Journal of Leukocyte Biology·Claire E OlingyCatherine C Hedrick
Oct 5, 2019·Clinical Pharmacokinetics·Xing JingChandrahas Sahajwalla
Dec 6, 2020·Current Opinion in Obstetrics & Gynecology·Kalika KamatOliver Dorigo
Feb 2, 2021·Frontiers in Oncology·Franklin NingChristina M Annunziata
Aug 25, 2020·Organic Letters·Xiaoyi WangRichard J Payne
Feb 25, 2020·Bulletin du cancer·Olivia Le SauxIsabelle Ray-Coquard
Aug 20, 2021·Stem Cell Research & Therapy·Matthew H ForsbergChristian M Capitini

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
flow cytometry

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.